Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy

Table 1

Characteristics of patients.

Variables
Age^*	53 ± 12.3 years	(26–71 years)
Gender
Male	0
Female	50
ECOG performance status
0	24
1	18
2	8
Height^**	155.6 ± 3.7 cm	(150–162 cm)
Body weight^**	55.1 ± 11.2 kg	(42–84 kg)
Body mass index^**	22.8 ± 4.4	(16.2–33.8)
The cycle in which patients developed grade 2 or 3 nausea despite standard antiemetic therapy
1	29
2	11
3	6
4	4
Type of cancer
Uterine cervical cancer	23
Uterine corpus cancer	22
Uterine carcinosarcoma	2
Ovarian cancer	2
Vaginal cancer	1
Regimen of anticancer chemotherapy
AP (adriamycin 60 mg/m^2, cisplatin 50 mg/m^2)	22
CPT-11/CDDP (irinotecan 60 mg/m^2, cisplatin 60 mg/m^2)	8
CDDP (cisplatin 50 mg/m^2)	5
FP (5-fluorouracil 700 mg/m^2  × 4 days, cisplatin 70 mg/m^2)^***	3
TP (paclitaxel 135 mg/m^2, cisplatin 50 mg/m^2)	3
EP (etoposide 100 mg/m^2  × 3 days, cisplatin 80 mg/m^2)	2
IP (ifosphamide 1.5 g/m^2  × 4 days, cisplatin 80 mg/m^2)	2
weekly CDDP (cisplatin 40 mg/m^2)^***	4
weekly TP (paclitaxel 50 mg/m^2, cisplatin 30 mg/m^2)^***	1

ECOG: Eastern Cooperative Oncology Group; CDDP: cisplatin.
^*Median ± S.D. (range).
^**Mean ± S.D. (range).
^***Combined with external pelvic irradiation (1.8 Gy/day).